TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25844322

Group type: EXPERIMENTAL
Intervention: Levetiracetam 62.5 mg BID
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Levetiracetam 125 mg BID
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Levetiracetam 250 mg BID
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 24424561

Group type: EXPERIMENTAL
Intervention: 80-kilovolt (peak) protocol with hybrid iterative reconstruction (HIR) (P2)
Number of subjects: 60

Group type: COMPARATOR
Intervention: 120-kilovolt (peak) protocol with filtered back projection (P1)
Number of subjects: 60
Study: 23022090

Group type: EXPERIMENTAL
Intervention: Real-time three-dimensional echocardiography
Number of subjects: 53
Study: 19577288

Group type: EXPERIMENTAL
Intervention: Filtek Supreme
Number of subjects: 35

Group type: COMPARATOR
Intervention: Z100
Number of subjects: 35
Study: 17602037

Group type: EXPERIMENTAL
Intervention: Desflurane in sitting position
Number of subjects: 48

Group type: COMPARATOR
Intervention: Desflurane in supine position
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Combined analysis of both positions
Number of subjects: 48
Study: 15385115

Group type: EXPERIMENTAL
Intervention: HER-2/neu overexpression
Number of subjects: 361

Group type: EXPERIMENTAL
Intervention: Response to first-line chemotherapy (CR + PR)
Number of subjects: 361

Group type: EXPERIMENTAL
Intervention: No response to first-line chemotherapy (SD + PD)
Number of subjects: 361
Study: 12161948

Group type: EXPERIMENTAL
Intervention: Risk matrix identification for medical personnel
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Biological risk assessment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chemical and allergic risk assessment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Manual handling of patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stress factor consideration
Number of subjects: 0
Study: 9862847

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA) therapy
Number of subjects: 548

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 548
Study: 1671380

Group type: EXPERIMENTAL
Intervention: Atenolol (50 mg)
Number of subjects: 878

Group type: EXPERIMENTAL
Intervention: Chlorthalidone (25 mg) with weight loss diet
Number of subjects: 878

Group type: EXPERIMENTAL
Intervention: Chlorthalidone (25 mg) with low sodium/high potassium diet
Number of subjects: 878

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 878
Study: 6868218

Group type: EXPERIMENTAL
Intervention: Emepronium bromide/flavoxate
Number of subjects: 20

Group type: COMPARATOR
Intervention: Emepronium bromide
Number of subjects: 20
Study: 31505542

Group type: EXPERIMENTAL
Intervention: l-DOPA
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: dextroamphetamine
Number of subjects: 7

Group type: COMPARATOR
Intervention: amantadine
Number of subjects: 7
Study: 29565228

Group type: EXPERIMENTAL
Intervention: Tigecycline
Number of subjects: 42

Group type: COMPARATOR
Intervention: Imipenem-cilastatin
Number of subjects: 42
Study: 29071873

Group type: EXPERIMENTAL
Intervention: 6X+6 strategy (6 cores in the suspected region and another 6 in the systematic prostate)
Number of subjects: 262

Group type: COMPARATOR
Intervention: 12+2X method (12 cores in the systematic prostate and 2 in the suspected region)
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 262
Study: 25127251

Group type: EXPERIMENTAL
Intervention: Theatre intervention
Number of subjects: 477

Group type: COMPARATOR
Intervention: Tutoring
Number of subjects: 477

Group type: COMPARATOR
Intervention: Control
Number of subjects: 477
Study: 22816536

Group type: EXPERIMENTAL
Intervention: Dual-chamber ICD or CRT-D devices with high rate cutoff (MADIT-RIT-Arm B)
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: Detection enhancements with long delay (MADIT-RIT-Arm C)
Number of subjects: 1500

Group type: COMPARATOR
Intervention: Standard programming (MADIT-RIT-Arm A)
Number of subjects: 1500
Study: 21205505

Group type: EXPERIMENTAL
Intervention: Liraglutide 1.8 mg/day
Number of subjects: 746

Group type: EXPERIMENTAL
Intervention: Liraglutide 1.2 mg/day
Number of subjects: 746

Group type: COMPARATOR
Intervention: Glimepiride 8 mg/day
Number of subjects: 746
Study: 18940392

Group type: EXPERIMENTAL
Intervention: Higher urinary D‐chiro‐inositol excretion
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Higher urinary myo‐ to D‐chiro‐inositol ratio
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Urinary D‐chiro‐inositol
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Urinary myo‐inositol
Number of subjects: 15
Study: 15781505

Group type: EXPERIMENTAL
Intervention: naloxone 0.25 microg . kg(‐1) . h(‐1)
Number of subjects: 46

Group type: COMPARATOR
Intervention: saline (control)
Number of subjects: 46
Study: 12535037

Group type: EXPERIMENTAL
Intervention: Caudal block using bupivacaine 0.15% with ketamine 0.5 mg x kg‐1 (n = 30)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Dorsal nerve block of the penis with bupivacaine 0.5% (n = 30)
Number of subjects: 60
Study: 10395629

Group type: EXPERIMENTAL
Intervention: Botulinum toxin (20 U injected into the internal anal sphincter on each side of the anterior midline)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Nitroglycerin ointment (0.2 percent applied twice daily for six weeks)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both treatments (crossover patients)
Number of subjects: 50
Study: 9332460

Group type: EXPERIMENTAL
Intervention: Cisplatin-based combination chemotherapy (vindesine and cisplatin, mitomycin, vindesine and cisplatin, etoposide and cisplatin alternating with vindesine and mitomycin)
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Cisplatin-based combination chemotherapy (EP/VM arm)
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Cisplatin-based combination chemotherapy (MVP and EP/VM arms)
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Cisplatin-based chemotherapy
Number of subjects: 203
Study: 8228364

Group type: EXPERIMENTAL
Intervention: Large-particle aerosol (LPA) administration of bivalent cold‐adapted influenza A vaccine
Number of subjects: 198

Group type: COMPARATOR
Intervention: Nose drops (ND) administration of bivalent cold‐adapted influenza A vaccine
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Large-particle aerosol (LPA) administration
Number of subjects: 198

Group type: COMPARATOR
Intervention: Nose drops (ND) administration
Number of subjects: 198
Study: 3777408

Group type: EXPERIMENTAL
Intervention: Halothane
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Enflurane
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 30

Group type: COMPARATOR
Intervention: Halothane, Enflurane, Isoflurane
Number of subjects: 30
Study: 30064627

Group type: EXPERIMENTAL
Intervention: DECADE brochures (A+D group)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Control group (A group)
Number of subjects: 87
Study: 27101256

Group type: EXPERIMENTAL
Intervention: Single-session computer-delivered cognitive bias modification for interpretation biases (CBM-I) for anxiety sensitivity (AS)
Number of subjects: 0
Study: 24512909

Group type: EXPERIMENTAL
Intervention: Infliximab plus Azathioprine
Number of subjects: 239

Group type: COMPARATOR
Intervention: Infliximab monotherapy
Number of subjects: 239

Group type: COMPARATOR
Intervention: Azathioprine monotherapy
Number of subjects: 239
Study: 22571563

Group type: EXPERIMENTAL
Intervention: Hypericum perforatum ointment applied twice daily for 4 weeks
Number of subjects: 10

Group type: COMPARATOR
Intervention: Vehicle ointment applied twice daily for 4 weeks
Number of subjects: 10
Study: 20976257

Group type: EXPERIMENTAL
Intervention: Exercise consultation
Number of subjects: 30

Group type: COMPARATOR
Intervention: Canada's Physical Activity Guide for Youth
Number of subjects: 30
Study: 18587712

Group type: EXPERIMENTAL
Intervention: Nurse care with nurse practitioners using flowcharts and motivational interviewing
Number of subjects: 793

Group type: COMPARATOR
Intervention: Physician care
Number of subjects: 793
Study: 15787665

Group type: EXPERIMENTAL
Intervention: Patient Participation (PP) and teaching programme
Number of subjects: 165

Group type: COMPARATOR
Intervention: Standard Consultation (SC)
Number of subjects: 165
Study: 11805785

Group type: EXPERIMENTAL
Intervention: Waters' projection
Number of subjects: 40

Group type: COMPARATOR
Intervention: CT scanning
Number of subjects: 40
Study: 10075325

Group type: EXPERIMENTAL
Intervention: Casein diet
Number of subjects: 9

Group type: COMPARATOR
Intervention: Soy protein diet
Number of subjects: 9

Group type: COMPARATOR
Intervention: Self-selected diet
Number of subjects: 9

Group type: COMPARATOR
Intervention: Casein and soy-protein diets
Number of subjects: 9
Study: 7598116

Group type: COMPARATOR
Intervention: < 1 meal/week (referent)
Number of subjects: 21185

Group type: EXPERIMENTAL
Intervention: 1 fish meal/week
Number of subjects: 21185

Group type: EXPERIMENTAL
Intervention: 2-4 fish meals/week
Number of subjects: 21185

Group type: EXPERIMENTAL
Intervention: >= 5 fish meals/week
Number of subjects: 21185

Group type: EXPERIMENTAL
Intervention: Omega 3 fatty acid intake
Number of subjects: 21185

Group type: EXPERIMENTAL
Intervention: Specific types of fish
Number of subjects: 21185
Study: 1672488

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Lidocaine (200 mg)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Fentanyl (200 micrograms)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Esmolol (150 mg)
Number of subjects: 80
Study: 6920332

Group type: EXPERIMENTAL
Intervention: Metronidazole prophylaxis
Number of subjects: 133
Study: 31770051

Group type: EXPERIMENTAL
Intervention: Intradermal (ID) injection of 9 µg hemagglutinin (HA)/strain
Number of subjects: 80

Group type: COMPARATOR
Intervention: Intramuscular (IM) injection of 15 µg HA/strain
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Intradermal (ID) injection of 9 µg HA/strain
Number of subjects: 80
Study: 30850406

Group type: EXPERIMENTAL
Intervention: Cardiac output-guided haemodynamic therapy algorithm for intravenous fluid and inotropic drug administration during and in the 6 hours following surgery (n=368)
Number of subjects: 734

Group type: COMPARATOR
Intervention: Standard care (n=366)
Number of subjects: 734
Study: 29021285

Group type: EXPERIMENTAL
Intervention: Vitamin D (511 IU/d from diet and a cholecalciferol supplement) for 10 weeks
Number of subjects: 24
Study: 25665498

Group type: EXPERIMENTAL
Intervention: Computer-tailored, pedometer-based PA intervention (booklet, non-blinded pedometer, Internet link for tailored advice)
Number of subjects: 274

Group type: COMPARATOR
Intervention: Control group (no intervention components)
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: Computer-tailored, pedometer-based PA intervention
Number of subjects: 274

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 274
Study: 23591659

Group type: EXPERIMENTAL
Intervention: PCM Cervical Disc
Number of subjects: 342

Group type: COMPARATOR
Intervention: ACDF
Number of subjects: 342
Study: 20621362

Group type: EXPERIMENTAL
Intervention: Video Clinical Global Impression (CGI)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Mean of at least two independent evaluations of the video CGI
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Video CGI
Number of subjects: 50
Study: 19430307

Group type: EXPERIMENTAL
Intervention: AIDSVAX B/E HIV‐1 candidate vaccine
Number of subjects: 196

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 196
Study: 17823649

Group type: EXPERIMENTAL
Intervention: risperidone 3 mg daily
Number of subjects: 55
Study: 15592332

Group type: EXPERIMENTAL
Intervention: Grapefruit juice (1.7 mg bergamottin)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 2 mg bergamottin
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 6 mg bergamottin
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 12 mg bergamottin
Number of subjects: 11

Group type: COMPARATOR
Intervention: Water
Number of subjects: 11
Study: 11315240

Group type: EXPERIMENTAL
Intervention: Hip protector
Number of subjects: 164

Group type: COMPARATOR
Intervention: Control (non-wearers)
Number of subjects: 164
Study: 9765764

Group type: EXPERIMENTAL
Intervention: Preoperative chemotherapy with or without postoperative radiotherapy
Number of subjects: 2

Group type: COMPARATOR
Intervention: Control group (no preoperative chemotherapy)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Preoperative chemotherapy
Number of subjects: 2
Study: 7990020

Group type: EXPERIMENTAL
Intervention: root planing plus a mixture of tetracycline and citric acid‐containing gel (RP + TC‐CAG group)
Number of subjects: 64

Group type: COMPARATOR
Intervention: root planing alone (RP group)
Number of subjects: 64

Group type: COMPARATOR
Intervention: tetracycline‐containing gel alone (TCG group)
Number of subjects: 64

Group type: COMPARATOR
Intervention: root planing plus tetracycline‐containing gel (RP + TCG group)
Number of subjects: 64
Study: 2658361

Group type: EXPERIMENTAL
Intervention: Prophylactic sclerotherapy
Number of subjects: 41

Group type: COMPARATOR
Intervention: Medical treatment (Control)
Number of subjects: 41
Study: 30428836

Group type: EXPERIMENTAL
Intervention: Paracetamol (scheduled pain treatment)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Placebo (corresponding placebo treatment)
Number of subjects: 95
Study: 28793003

Group type: EXPERIMENTAL
Intervention: Axillary drainage
Number of subjects: 240

Group type: COMPARATOR
Intervention: No axillary drainage
Number of subjects: 240
Study: 24817695

Group type: EXPERIMENTAL
Intervention: Antioxidant vitamins C (1 g) and E (400 IU)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 23647804

Group type: EXPERIMENTAL
Intervention: Cognitive training (48 sessions over 12 weeks)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Wait list control
Number of subjects: 41
Study: 20053349

Group type: EXPERIMENTAL
Intervention: Oxandrolone 0.03 mg/kg/d
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Oxandrolone 0.06 mg/kg/d
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Oxandrolone 0.03 mg/kg/d or 0.06 mg/kg/d
Number of subjects: 133

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 133
Study: 18434455

Group type: EXPERIMENTAL
Intervention: Topical skin coolant spray
Number of subjects: 92

Group type: COMPARATOR
Intervention: Standard method (control group)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Both groups (study and control)
Number of subjects: 92
Study: 16538125

Group type: EXPERIMENTAL
Intervention: Silicone hydrogel lens (lotrafilcon A lenses, Focus NIGHT & DAY)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Conventional hydrogel lenses (etafilcon A or polymacon)
Number of subjects: 88
Study: 12825305

Group type: EXPERIMENTAL
Intervention: ephedrine-rocuronium
Number of subjects: 80

Group type: COMPARATOR
Intervention: placebo-rocuronium
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: ephedrine-atracurium
Number of subjects: 80

Group type: COMPARATOR
Intervention: placebo-atracurium
Number of subjects: 80
Study: 10993853

Group type: EXPERIMENTAL
Intervention: GR-II stent
Number of subjects: 755

Group type: COMPARATOR
Intervention: Palmaz-Schatz stent
Number of subjects: 755
Study: 8889425

Group type: EXPERIMENTAL
Intervention: Ibuprofen arginine (400 mg)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Morphine sulphate (5 mg)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Morphine sulphate (10 mg)
Number of subjects: 120
Study: 1797888

Group type: EXPERIMENTAL
Intervention: Allopurinol (50 mg p.o. q.i.d.)
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: DMSO (500 mg p.o. q.i.d.)
Number of subjects: 177

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 177
Study: 7316037

Group type: EXPERIMENTAL
Intervention: Closed suction catheter with antibiotic irrigation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Closed suction catheter with povidone-iodine irrigation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard open wound care with delayed primary closure
Number of subjects: 0
Study: 31794857

Group type: EXPERIMENTAL
Intervention: Self-management exercise program (5 sessions) + spa therapy (18 days)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Control group (spa therapy only, 18 days)
Number of subjects: 123
Study: 31096309

Group type: EXPERIMENTAL
Intervention: Statin therapy (rosuvastatin)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Statin therapy
Number of subjects: 0
Study: 28651338

Group type: EXPERIMENTAL
Intervention: TPF (docetaxel, cisplatin, 5-fluorouracil)
Number of subjects: 119

Group type: COMPARATOR
Intervention: PF (cisplatin/5-fluorouracil)
Number of subjects: 119
Study: 25654519

Group type: EXPERIMENTAL
Intervention: Tailored exercise program (6-month, twice-a-week)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 60
Study: 24015719

Group type: EXPERIMENTAL
Intervention: Whey protein (1.4 g·kg body mass⁻¹)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Carbohydrate (1.1 g·kg body mass⁻¹)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Soy protein (1.4 g·kg body mass⁻¹)
Number of subjects: 63
Study: 21414093

Group type: EXPERIMENTAL
Intervention: Paroxetine (20 mg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: No drug
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 19204218

Group type: EXPERIMENTAL
Intervention: Exercise energy expenditure of 4 kilocalories per kilogram of body weight per week
Number of subjects: 430

Group type: EXPERIMENTAL
Intervention: Exercise energy expenditure of 8 kilocalories per kilogram of body weight per week
Number of subjects: 430

Group type: EXPERIMENTAL
Intervention: Exercise energy expenditure of 12 kilocalories per kilogram of body weight per week
Number of subjects: 430

Group type: COMPARATOR
Intervention: Nonexercise control group
Number of subjects: 430
Study: 17381533

Group type: EXPERIMENTAL
Intervention: dCa 1.5 mmol/L for three months, then dCa 1.25 mmol/L for three months (ABD-treated group)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: dCa 1.5 mmol/L for three months, then dCa 1.25 mmol/L for three months (sHPT-treated group)
Number of subjects: 65

Group type: COMPARATOR
Intervention: dCa 1.75 mmol/L (ABD-control group)
Number of subjects: 65

Group type: COMPARATOR
Intervention: dCa 1.75 mmol/L (sHPT-control group)
Number of subjects: 65
Study: 15446659

Group type: EXPERIMENTAL
Intervention: High cognitive effort strategies during practice
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Minimal cognitive processing strategies during practice
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Combination of effortful and automatic strategies
Number of subjects: 29
Study: 11222826

Group type: EXPERIMENTAL
Intervention: Prone computed tomography scanning
Number of subjects: 69

Group type: COMPARATOR
Intervention: Supine computed tomography scanning
Number of subjects: 69
Study: 9688063

Group type: EXPERIMENTAL
Intervention: Cmin method
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ABCM method
Number of subjects: 0
Study: 8090456

Group type: EXPERIMENTAL
Intervention: Various risk factors for graft failure
Number of subjects: 457

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 457
Study: 2682023

Group type: EXPERIMENTAL
Intervention: Combined antegrade and retrograde cardioplegia
Number of subjects: 59

Group type: COMPARATOR
Intervention: Antegrade cardioplegia
Number of subjects: 59
Study: 782955

Group type: EXPERIMENTAL
Intervention: Hydrocortisone 17-butyrate
Number of subjects: 23

Group type: COMPARATOR
Intervention: Betamethasone 17-valerate
Number of subjects: 23
Study: 30929637

Group type: EXPERIMENTAL
Intervention: Machine learning model using random forest algorithm
Number of subjects: 2064

Group type: COMPARATOR
Intervention: Conventional US diagnosis by radiologist
Number of subjects: 2064

Group type: COMPARATOR
Intervention: Conventional US and real-time elastography diagnosis by radiologist
Number of subjects: 2064
Study: 29117238

Group type: EXPERIMENTAL
Intervention: TDF/FTC/LPVr, ABC/ddI/LPVr, TDF/FTC/DRVr
Number of subjects: 228
Study: 24737460

Group type: EXPERIMENTAL
Intervention: Memantine (20 mg/day)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 23116237

Group type: EXPERIMENTAL
Intervention: Oral hormone therapy (o-HT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Transdermal hormone therapy (t-HT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 21606296

Group type: EXPERIMENTAL
Intervention: 80-kVp protocol with low-dose contrast material (444 mg I/kg body weight) delivered over 15 seconds
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: 80-kVp protocol with low-dose contrast material
Number of subjects: 111

Group type: COMPARATOR
Intervention: 120-kVp protocol with standard-dose contrast material (600 mg I/kg) delivered over 30 seconds
Number of subjects: 111

Group type: COMPARATOR
Intervention: 120-kVp protocol with standard-dose contrast material
Number of subjects: 111
Study: 19339135

Group type: EXPERIMENTAL
Intervention: High counseling combined with bupropion or nicotine patch
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: Low counseling combined with bupropion or nicotine patch
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: High counseling
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: Low counseling
Number of subjects: 260
Study: 17412784

Group type: EXPERIMENTAL
Intervention: Isocapnic hypoxia (arterial oxygen saturation 80%)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Normoxia
Number of subjects: 10
Study: 15389222

Group type: EXPERIMENTAL
Intervention: Abciximab and half-dose reteplase followed by conventional medical therapy (with referral for emergency rescue PTCA allowed in selected cases)
Number of subjects: 900

Group type: EXPERIMENTAL
Intervention: Abciximab and half-dose reteplase followed by emergency angioplasty
Number of subjects: 900

Group type: EXPERIMENTAL
Intervention: Abciximab and half-dose reteplase
Number of subjects: 900
Study: 11590972

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 14

Group type: COMPARATOR
Intervention: Typical antipsychotic treatment
Number of subjects: 14
Study: 9850430

Group type: EXPERIMENTAL
Intervention: Phenylpropanolamine 50 mg administered at 22.00 h
Number of subjects: 8

Group type: COMPARATOR
Intervention: Phenylpropanolamine 50 mg administered at 10.00 h
Number of subjects: 8
Study: 7522193

Group type: EXPERIMENTAL
Intervention: Spinal cord stimulation (SCS)
Number of subjects: 51
Study: 2604449

Group type: EXPERIMENTAL
Intervention: Blisterfilm dressing
Number of subjects: 0

Group type: COMPARATOR
Intervention: Gauze dressing
Number of subjects: 0